Ordering
Available Variants5 mg
CHA.41926-5mg
Price
€182.40
Available – Dispatch in 14 days
25 mg
CHA.41926-25mg
Price
€667.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.41926-5mg | €182.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.41926-25mg | €667.20 |
≥98% (HPLC), powder, BET bromodomain protein inhibitor
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C23H25ClN4O2S |
|---|---|
| CAS Number | 1268524-70-4 |
| Molecular Weight | 456.99 |
| UNSPSC Code | 41106609 |
| PubChem Substance ID | 329825941 |
| NACRES | NA.77 |
| MDL number | MFCD22683748 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
(+)-JQ1, also known by its CAS number 1268524-69-1, is a small molecule inhibitor that has garnered significant attention in the scientific community due to its potential therapeutic applications. This compound has been shown to selectively inhibit the bromodomain and extra-terminal domain (BET) family of proteins, which play a crucial role in the regulation of gene transcription. By binding to the acetyl-lysine recognition pocket of BET proteins, (+)-JQ1 disrupts the interaction between these proteins and chromatin, leading to the suppression of transcriptional activity. As a result, (+)-JQ1 has been investigated as a potential treatment for various diseases, including cancer, inflammation, and cardiovascular disorders, where BET proteins have been implicated in disease pathogenesis. Further research is needed to fully elucidate the therapeutic potential of (+)-JQ1 and its potential as a novel therapeutic agent.
